MARKET

VXRT

VXRT

VAXART
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.52
+0.30
+5.75%
After Hours: 5.58 +0.06 +1.09% 19:57 04/13 EDT
OPEN
5.18
PREV CLOSE
5.22
HIGH
5.56
LOW
5.13
VOLUME
2.89M
TURNOVER
--
52 WEEK HIGH
24.90
52 WEEK LOW
1.640
MARKET CAP
650.07M
P/E (TTM)
-16.0980
1D
5D
1M
3M
1Y
5Y
ORMP: Company Advancing Oral COVID-19 Vaccine
By M. Marin NASDAQ:ORMP | NASDAQ:VXRT | NASDAQ:ALT READ THE FULL ORMP RESEARCH REPORT Advantages include ease of storage & distribution, plus potential to overcome vaccine hesitancy Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) has announced the formation of a...
Zacks Small Cap Research · 03/25 15:46
Effective Diagnostics Help to Tame the Spread of the Pandemic
, /PRNewswire/ -- Recent reports from across the country clearly show that infection cases are stabilizing. Additionally, vaccines are being administrated at an effective rate, which contributes to a more relaxed attituded towards the pandemic. As a resul...
PR Newswire - PRF · 03/24 13:00
Diagnostic Improvements Play a Key Role in the Abatement of the Pandemic
NEW YORK, March 23, 2021 (PR Newswire Europe via COMTEX) -- - FinancialBuzz.com News Commentary NEW YORK, March 23, 2021 /PRNewswire/ --Since the pandemic's...
PR Newswire Europe · 03/23 13:03
Vaxart Stock Trades Higher On Increased Volume: A Technical Analysis
Vaxart Inc. (NASDAQ: VXRT) shares gained 2.69% Tuesday on increased volume, closing the session at $7.06.  The stock was trending on StockTwits, and there was no company evident news to explain the volume increase.
Benzinga · 03/16 20:12
Vaxart: The Show Me Story Still Has Potential, Says Analyst
The stock market has been pulled aggressively in both directions in 2021, but the moves are relatively tame compared to the wild ride of Vaxart (VXRT) stock. Toward the end of January, shares more than doubled in less than a week due to the formidable pair...
TipRanks · 03/12 02:05
T-Cell responses remain intact against new COVID-19 variants: New study
Scientists are still uncertain as to how quickly antibody responses against COVID-19 disappear and the level of antibody-driven protection against new coronavirus strains.However, the other component of the adaptive immunity
Seekingalpha · 03/09 14:36
Bireme Capital: “Vaxart, Inc. is Exhibiting Classic Pretender Signals”
Bireme Capital, an investment management firm, published its fourth-quarter 2020 Investor Letter – a copy of which can be downloaded here. A net return of 47.1% was recorded by the fund for the year end 2020, outperforming its S&P500 benchmark that deliver...
Insider Monkey · 03/05 15:11
Vaxart to Present at the H.C. Wainwright Global Life Sciences Conference
SOUTH SAN FRANCISCO, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that manageme...
GlobeNewswire · 03/04 21:01
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VXRT. Analyze the recent business situations of VAXART through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VXRT stock price target is 13.33 with a high estimate of 17.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 156
Institutional Holdings: 36.45M
% Owned: 30.95%
Shares Outstanding: 117.77M
TypeInstitutionsShares
Increased
46
11.85M
New
41
2.43M
Decreased
26
9.00M
Sold Out
29
6.60M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.86%
Pharmaceuticals & Medical Research
+0.68%
Key Executives
Chairman/Director
Wouter Latour
Chief Executive Officer/Chief Financial Officer/Director
Andrei Floroiu
Chief Accounting Officer/Vice President/Controller
Margaret Echerd
Chief Scientific Officer
Sean Tucker
Other
David Taylor
Lead Director/Independent Director
Robert Yedid
Director
Steven Boyd
Director
Keith Maher
Independent Director
Todd Davis
Independent Director
Michael Finney
Director
I. Keith Maher
Independent Director
Anne VanLent
Independent Director
Bob Yedid
Independent Director
Karen Wilson
Declaration Date
Dividend Per Share
Ex-Div Date
10/25/2012
Dividend USD 1.108
11/09/2012
About VXRT
Vaxart, Inc., formerly Aviragen Therapeutics, Inc., is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options. Its products include vapendavir, an oral treatment for human rhinovirus (HRV) upper respiratory infections in moderate-to-severe asthmatics in Phase IIb SPIRITUS trial; BTA585, an oral fusion (F) protein inhibitor in Phase II development for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in Phase II development for condyloma caused by human papillomavirus Types 6 and 11. It has preclinical RSV non-fusion inhibitor program. It has focused its research and drug development capabilities on discovering and developing small molecule compounds that can prevent or treat infectious diseases.

Webull offers kinds of Vaxart Inc stock information, including NASDAQ:VXRT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VXRT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VXRT stock methods without spending real money on the virtual paper trading platform.